Clinical trials: Elevated Risk of Cardiovascular Disease
Aortic Valve Stenosis
Medtronic CoreValve REDO Study
The proposed investigation is a prospective, multicenter, non-randomized study to evaluate the immediate benefits (at discharge and at 30 days) in terms of performance and safety of the implantation of the Medtronic CoreValve PAV…
- Trial name
- REDO (NCT01051310)
- Testing
- Medtronic CoreValve System
- Where
- 3 sites in Germany, Netherlands
- Volunteers
- 18 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Pulmonary Embolism, Deep Vein Thrombosis
The Angel® Catheter Pivotal Clinical Trial
The primary objective of this multicenter, prospective, single arm clinical trial is to evaluate the safety and effectiveness of the Angel® Catheter in subjects at high risk of PE, and with recognized contraindications to…
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism, Trauma
- Trial name
- NCT02186223
- Testing
- The Angel® Catheter
- Where
- 21 sites in United States
- Volunteers
- 172 people
- Sponsor
- BiO2 Medical
Obstructive Sleep Apnea, Coronary Disease
Patients with Coronary Artery Disease or At High Cardiovascular Risk: Measuring Compliance with Treatment for Obstructive Sleep Apnea Syndrome
Obstructive sleep apnea (OSA) is a sleep disorder characterised by partial or total obstruction of the oro-pharyngeal carrefour during sleep.
- Conditions
- Obstructive Sleep Apnea, Coronary Disease, Cardiovascular Diseases
- Trial name
- PACOAM (NCT06568159)
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Montpellier
Acute Coronary Syndrome (ACS), High Bleeding Risk(HBR)
Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk
Patients with acute coronary syndrome (ACS) who have both high ischemic risk and high bleeding risk represent a challenging population following percutaneous coronary intervention (PCI), as prolonged dual antiplatelet therapy…
- Conditions
- Acute Coronary Syndrome (ACS), High Bleeding Risk(HBR), Coronary Artery Disease (CAD)
- Trial name
- NCT07374718
- Testing
- IVUS-guided BioFreedomTM Drug-Coated Stent Implantation + 1-Month DAPT Followed by 11-Month P2Y12 Inhibitor Monotherapy, Angiography-guided Conventional Drug-Eluting Stent Implantation + 12-Month Dual Antiplatelet Therapy (Aspirin + P2Y12 Inhibitor)
- Where
- China
- Volunteers
- 468 people
- Sponsor
- Shenyang Northern Hospital
Multiple Myeloma
MUK Nine b: OPTIMUM Treatment Protocol
To determine whether a combination of four novel agents bortezomib(Velcade), lenalidomide (Revlimid), Daratumumab (Darzalex) \& dexamethasone in combination with low-dose cyclophosphamide is sufficiently active in a high risk…
- Trial name
- MUKnineb (NCT03188172)
- Testing
- Cyclophosphamide, Bortezomib, Lenalidomide
- Where
- 21 sites in United Kingdom
- Volunteers
- 95 people
- Sponsor
- University of Leeds
Cardiac Disease, PCI
Comparison of the Supraflex Cruz 60 Micron Versus the Ultimaster Tansei 80 Micron in HBR PCI Population
The study compares the outcome of the ultrathin stent strut Supraflex Cruz stent to the thin stent strut Ultimaster Tansei stent in a PCI population at high risk for bleeding (HBR).
- Conditions
- Cardiac Disease, PCI, High Bleeding Risk
- Trial name
- NCT04500912
- Testing
- Supraflex Cruz 60 Micron, Ultimaster Tansei 80 Micron
- Where
- 11 sites in Netherlands
- Volunteers
- 736 people
- Sponsor
- Pieter C.Smits
Acute Coronary Syndrome
Efficacy of Ticagrelor vs Clopidogrel in High-risk NSTE-ACS Patients Undergoing Early PCI
The goal of acute coronary syndrome (ACS) therapy is to successfully restore both epicardial blood flow and myocardial perfusion.
- Trial name
- NCT02201667
- Testing
- Ticagrelor, clopidogrel, Aspirin
- Where
- China
- Volunteers
- 444 people
- Sponsor
- RenJi Hospital
Atherosclerotic Cardiovascular Disease
Clinical Assessment and Targeted Imaging to Characterize High-Risk Atherosclerotic Cardiovascular Disease of Survivors in SJLIFE
Childhood cancer survivors are at increased risk for premature atherosclerotic cardiovascular disease (ASCVD) due to cancer treatment-related exposures, including radiation therapy and platinum-based chemotherapy.
- Trial name
- NCT07594392
- Testing
- Coronary Artery Calcium Scan, Carotid Artery Ultrasound, Lipoprotein(a) Measurement
- Where
- United States
- Volunteers
- 650 people
- Sponsor
- St. Jude Children's Research Hospital
Non-ST Elevated Myocardial Infarction
Low Risk Non ST Elevation Myocardial Infarction With or Without Intensive Care Unit Admission
Favourable in-hospital outcome is observed in numerous patients after Non ST myocardial infarction (NSTEMI) with invasive strategy but European guidelines proposed systematic intensive care unit monitoring up to 24 h in lower…
- Trial name
- SELECTNSTEMI (NCT05153889)
- Testing
- Hospitalized in Intensive care unit, Hospitalized in General cardiology ward
- Where
- 3 sites in France
- Volunteers
- 320 people
- Sponsor
- University Hospital, Montpellier
Multiple Myeloma
Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients
In the phase I trial, dose escalation of chidamide will be performed at 4 different dosages (15mg, 20mg, 25mg, 30mg) for optimal dosage, in the phase II trial, the safety and efficacy of chidamide+VRD will be compared with that…
- Trial name
- NCT04025450
- Testing
- Chidamide+VRD, VRD
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Atrial Fibrillation, Hypertension
Irbesartan for the Prevention of Atrial Arrhythmias and Cardiac Electrical Remodeling in Patients With Hypertension and Permanent Pacemakers
The purpose of this study is to determine whether irbesartan will reduce the rate of recurrent atrial high rate episodes and the development of clinical sustained atrial fibrillation in patients with hypertension and permanent…
- Trial name
- NCT00225667
- Testing
- Irbesartan
- Where
- Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Connolly, Stuart, M.D.
Coronary Artery Disease
A Randomized Controlled Trial With Resolute Onyx in One Month Dual Antiplatelet Therapy (DAPT) for High-Bleeding Risk Patients
The purpose of this study is to evaluate the clinical safety and effectiveness of the Resolute Onyx stent in subjects deemed at high risk for bleeding and/or medically unsuitable for more than 1 month DAPT treatment receiving…
- Trial name
- Onyx ONE (NCT03344653)
- Testing
- Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System, Biosensors BioFreedom BA9 Drug Coated Coronary Stent
- Where
- 89 sites in Australia, Austria and 21 more
- Volunteers
- 2,000 people
- Sponsor
- Medtronic Vascular
Pregnancy Induced Hypertension
Optical Coherence Tomography Angiography Compared to Maternal Doppler in Screening for Hypertension in Pregnancy
Pregnancy related hypertension is one of the most prevalent obstetric complications. The aim of the study is to evaluate the validity and sensitivity of OCT angiography in prediction of pregnancy induced hypertensive disorders in…
- Trial name
- NCT05330949
- Testing
- Optical coherence Tomography Angiography, Uterine artry doppler
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Minia University
Pericarditis
Pericardial Imaging Study
The pericardium is a thin, double-layered sac around the heart that helps reduce friction as the heart moves. When this sac gets inflamed, it is called pericarditis, which can cause serious health problems and even be…
- Trial name
- NCT07245849
- Testing
- 18F-FDG PET/CT
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Atherosclerosis
The Effect of Vitamin D Repletion on Small Low Density Lipoprotein (LDL) Particle Number in Subjects at Elevated Cardiovascular Risk
Vitamin D is a fat-soluble vitamin that is naturally present in very few foods, added to others, and available as a dietary supplement.
- Trial name
- NCT01008384
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Rockefeller University
Type 2 Diabetes, Cardiovascular Complication
Study on the Predictive Value of High-sensitivity Cardiac Troponin I, N-terminal Pro-B-natriuretic Peptide, and Soluble Suppression of Tumorigenesis-2 for Mortality and the Development of Cardiovascular Events in Patients With Type 2 Diabetes (Diabetes-CV)
The Diabetes-CV study is an observational study designed to assess the prognostic value of serum cardiac damage markers high-sensitivity cardiac troponin I (hs-cTnI), N-terminal pro-B-natriuretic peptide (NT-proBNP), and soluble…
- Trial name
- Diabetes-CV (NCT06902857)
- Where
- Italy
- Volunteers
- 964 people
- Sponsor
- Istituto Nazionale di Ricovero e Cura per Anziani
Coronary Artery Disease, Percutaneous Coronary Intervention
Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy
The primary aim of this study is to evaluate the efficacy and safety of novel P-CAB (tegoprazan 50 mg once daily) as compared with standard PPI (rabeprazole 20 mg once daily) for protection of GI events in patients with known…
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome, Myocardial Infarction
- Trial name
- PROTECT-HBR (NCT04416581)
- Testing
- PPI, P-CAB 50
- Where
- 45 sites in South Korea
- Volunteers
- 3,320 people
- Sponsor
- Duk-Woo Park, MD
Metabolic Syndrome
Canola Oil Multicentre Intervention Trial
The purpose of the study is to examine how the consumption of different dietary oil varieties affects a broad range of metabolic responses that are important in the development of cardiovascular diseases.
- Trial name
- COMIT (NCT01351012)
- Testing
- Corn and safflower oil, Canola oil, High oleic acid canola oil
- Where
- Canada
- Volunteers
- 140 people
- Sponsor
- University of Manitoba
Dyslipidemia
A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease
This is a double-blind, randomized study designed to compare the efficacy and safety of two fixed combinations of fenofibrate / simvastatin 145/20 mg and fenofibrate / simvastatin 145/40 mg tablets vs.
- Trial name
- NCT01674712
- Testing
- Fixed Combination of Fenofibrate/simvastatin 145/20 mg, Simvastatin 20 mg, Fenofibrate 145 mg
- Where
- 69 sites in Argentina, Czechia and 5 more
- Volunteers
- 575 people
- Sponsor
- Abbott
Pre-hypertension, Hypertension
Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of Hypertension
The investigators aim to evaluate subjects at high risk of future development of hypertension, those with a family history of hypertension and/or that already have high normal(SBP 120-139 mmHg or DBP 80-89 mmHg) blood pressure.
- Trial name
- NCT01202175
- Testing
- Nebivolol
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.